Drive-through diagnostic testing? | Diaceutics

Drive-through diagnostic testing?

December 13th, 2017



A story in the UK press on 21 November 2017, Cancer tests in supermarket car parks in bid to boost detection rates, elicited the comment from Diaceutics of “Now that’s progress!” Our vision is that better testing leads to better patient outcomes and earlier diagnosis in the patient journey is a big part of that. The article also stimulated an animated discussion on public health policy. This story described an NHS (UK) pilot scheme in which smokers and ex-smokers were invited to a mobile clinic at a local shopping centre. Those showing recognized symptoms of lung disease were invited to undergo an immediate CT scan. The scheme “quadrupled the number of cases of lung cancer detected at stage one or two, when it is more likely to be curable.” The NHS has plans for further easy access and home diagnostic testing to improve its cancer survival rates. But is this the way to go?

A Diaceutics team member who had recently attended the Lung Cancer Congress in Barcelona described how participants had been given a mobile app to vote on whether or not population screening is necessary. Even though participation was not particularly high, most doctors and pathologists in the room voted ‘no’. One issue was the radiation encountered in these screening programs. Another was the effects of suddenly learning that your symptoms need further investigation. The general consensus was that although screening is beneficial, it would be more cost-effective to invest in primary prevention and stop people smoking in the first place or help them quit. What concerned our colleague, however, was that molecular testing for targeted patients was not a consideration in the discussion, which we at Diaceutics believe should be high priority.

Another colleague was worried that easy-to-access diagnostic testing or public health screening initiatives such as this one can come about through political pressure, or the appearance of doing something rather than nothing. However, these programs may actually undermine clinical effectiveness, as could be the issue with some aspects of breast cancer screening, where the routine screening of all women over a certain age, rather than women of any age with a specific genetic risk, can create overdiagnosis of a relatively benign condition such as ductal hyperplasia. A worse outcome would be if a poorly-planned or executed screening initiative takes funding away from primary care initiatives. Lung cancer is not just the preserve of people with a smoking history. Will those without risk factors miss out on walk-up testing?

Whatever the reaction, this pilot scheme can be viewed as a step forward in giving patients much earlier access to diagnostic tests that can set the course to the right targeted treatment or highlight any susceptibility for a particular disease. Diagnostic testing, with the added benefit of being free from side effects, is working its way down the chain towards the people that matter – the patients – something we at Diaceutics are happy to endorse.

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
View all publications
Facebook
Twitter
YouTube
LinkedIn